Biohaven Ltd BHVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BHVN is a good fit for your portfolio.
News
-
Biohaven Announces Proposed Public Offering of Common Shares
-
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
-
Biohaven Told That FDA Won't Review NDA Application for Troriluzole
Trading Information
- Previous Close Price
- $43.77
- Day Range
- $42.55–45.60
- 52-Week Range
- $12.35–62.21
- Bid/Ask
- $42.40 / $45.25
- Market Cap
- $3.60 Bil
- Volume/Avg
- 1.0 Mil / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 239
- Website
- https://www.biohavenpharma.com
Comparables
Valuation
|
Metric
|
BHVN
|
RYTM
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.30 | 13.48 | 1.63 |
Price/Sales | — | 28.69 | 477.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
BHVN
RYTM
PLRX
Financial Strength
|
Metric
|
BHVN
|
RYTM
|
PLRX
|
|---|---|---|---|
Quick Ratio | 7.13 | 5.27 | 17.43 |
Current Ratio | 7.98 | 5.58 | 17.72 |
Interest Coverage | — | −13.26 | −145.34 |
Quick Ratio
BHVN
RYTM
PLRX
Profitability
|
Metric
|
BHVN
|
RYTM
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −70.70% | −46.12% | −22.68% |
Return on Equity (Normalized) | −89.63% | −76.97% | −24.50% |
Return on Invested Capital (Normalized) | −83.52% | −76.40% | −28.46% |
Return on Assets
BHVN
RYTM
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nbvqxgyyrk | Hlpnv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xwfvhkkd | Gnlzcd | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qnzrxvq | Ynxwkt | $98.9 Bil | |
MRNA
| Moderna Inc | Slfjllwqw | Xbq | $39.7 Bil | |
ARGX
| argenx SE ADR | Frfcpgv | Xbqsf | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Nsgsxzhht | Mqdb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zmfpwlgth | Vjyztqj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Btcndmfr | Hdsqss | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Frdwxmsgkz | Vndwgvz | $12.3 Bil | |
INCY
| Incyte Corp | Wpjyztfl | Qplfbwl | $11.8 Bil |